CMTx Biotech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

CMTx Biotech is a U.S.-based biotech firm leveraging a drug repurposing and rescue platform to develop host-directed therapeutics for CBRN threats and severe infections. Its lead asset, incyclinide, has completed IND-enabling studies, and a second candidate, CMTx R2, is an internationally approved drug being repositioned. The company is led by a seasoned management team with expertise in drug development and commercialization, and it maintains collaborations with key academic institutions to advance its pipeline. CMTx operates as a pre-revenue, private entity targeting government and public health markets for medical countermeasures.

BiodefenseInfectious Diseases

Technology Platform

Drug rescue, repositioning, and repurposing platform focused on developing Host-Directed Therapeutics (HDTs) that modulate the host immune response to treat CBRN threats and infections.

Opportunities

The growing biodefense budget of the U.S.

government and increased focus on pandemic preparedness create a strong, non-commercial market for medical countermeasures.

The host-directed, threat-agnostic therapeutic approach could address multiple high-priority threats with a single product, enhancing its value for the Strategic National Stockpile.

Risk Factors

The company is pre-revenue and reliant on securing government grants or venture funding to advance its pipeline.

Clinical development for CBRN threats faces unique regulatory hurdles and ultimately depends on government procurement decisions, which are unpredictable.

Efficacy of repurposed drugs in new, severe indications is unproven.

Competitive Landscape

CMTx competes in the biodefense space with larger firms like Emergent BioSolutions, Ology Bioservices, and pharmaceutical companies with government contracts, as well as other biotechs developing host-directed therapies. Its differentiation lies in its focused repurposing strategy aimed at speed and capital efficiency, but it faces competition for limited government funding and scientific mindshare.

More companies in Small Molecule Drugs →More companies in United States →